MA32095B1 - مثبطات aldh -2 في علاج الإدمان - Google Patents

مثبطات aldh -2 في علاج الإدمان

Info

Publication number
MA32095B1
MA32095B1 MA33106A MA33106A MA32095B1 MA 32095 B1 MA32095 B1 MA 32095B1 MA 33106 A MA33106 A MA 33106A MA 33106 A MA33106 A MA 33106A MA 32095 B1 MA32095 B1 MA 32095B1
Authority
MA
Morocco
Prior art keywords
aldh
addiction
inhibitors
treatment
amphetamines
Prior art date
Application number
MA33106A
Other languages
English (en)
French (fr)
Inventor
Yaroslav Bilokin
Elfatih Elzein
Jeff Zablocki
Michael Organ
Thao Perry
Tetsuya Kobayashi
Matthew Abelman
Rao Kalla
Peidong Fan
Ivan Diamond
Robert Jiang
Maria Pia Arolfo
Xiaofen Li
Lina Yao
Zhan Jiang
Wing Ming Keung
Guoxin Tao
Original Assignee
Endowment For Res In Human Biology Inc
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endowment For Res In Human Biology Inc, Gilead Palo Alto Inc filed Critical Endowment For Res In Human Biology Inc
Publication of MA32095B1 publication Critical patent/MA32095B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
MA33106A 2008-01-24 2010-08-23 مثبطات aldh -2 في علاج الإدمان MA32095B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/051862 WO2009094028A1 (en) 2008-01-24 2008-01-24 Aldh-2 inhibitors in the treatment of addiction

Publications (1)

Publication Number Publication Date
MA32095B1 true MA32095B1 (ar) 2011-02-01

Family

ID=39731733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33106A MA32095B1 (ar) 2008-01-24 2010-08-23 مثبطات aldh -2 في علاج الإدمان

Country Status (13)

Country Link
EP (1) EP2254878A1 (ar)
JP (1) JP2011510072A (ar)
KR (1) KR20100130589A (ar)
CN (1) CN101925590A (ar)
AU (1) AU2008348372A1 (ar)
BR (1) BRPI0822129A2 (ar)
CA (1) CA2712750A1 (ar)
EC (1) ECSP10010417A (ar)
IL (1) IL207127A0 (ar)
MA (1) MA32095B1 (ar)
MX (1) MX2010008111A (ar)
WO (1) WO2009094028A1 (ar)
ZA (1) ZA201004671B (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161648A (zh) * 2011-02-18 2011-08-24 中国药科大学 具有选择性雌激素受体调节活性的异黄酮类化合物的制备方法及其用途
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TWI468403B (zh) * 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之aldh-2抑制劑
EP3697415A4 (en) * 2017-10-16 2021-07-14 Amygdala Neurosciences, Inc. POLYTHERAPY FOR THE PREVENTION OF ADDICTION
CN108276374B (zh) * 2018-03-29 2020-01-31 天津科技大学 黄酮类芳香化酶抑制剂及其制备方法与应用
CN110922394B (zh) * 2019-11-21 2021-04-06 中国科学院宁波材料技术与工程研究所 一种基于天然黄酮类化合物的生物基本征阻燃环氧树脂前驱体及其制备方法和应用
WO2023235753A2 (en) * 2022-05-31 2023-12-07 University Of Maryland, Baltimore Aldh2 inhibitors and methods of use thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU162377B (ar) * 1970-05-27 1973-02-28
US4166862A (en) * 1971-05-25 1979-09-04 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Animal feed containing anabolic isoflavones
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
AU3899199A (en) * 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
AU2002367953C1 (en) * 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
KR20060011785A (ko) * 2002-06-27 2006-02-03 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. Aldh 억제에 유용한 화합물
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
PL377180A1 (pl) * 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
CA2653056A1 (en) * 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
KR20100097675A (ko) * 2007-11-06 2010-09-03 씨브이 쎄러퓨틱스, 인코포레이티드 정신 장애 치료에 있어서의 aldh-2 억제제

Also Published As

Publication number Publication date
CA2712750A1 (en) 2009-07-30
ZA201004671B (en) 2011-03-30
CN101925590A (zh) 2010-12-22
AU2008348372A1 (en) 2009-07-30
BRPI0822129A2 (pt) 2015-06-23
IL207127A0 (en) 2010-12-30
WO2009094028A1 (en) 2009-07-30
EP2254878A1 (en) 2010-12-01
JP2011510072A (ja) 2011-03-31
MX2010008111A (es) 2010-11-30
ECSP10010417A (es) 2010-11-30
KR20100130589A (ko) 2010-12-13

Similar Documents

Publication Publication Date Title
MA32095B1 (ar) مثبطات aldh -2 في علاج الإدمان
MA30434B1 (fr) Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA32684B1 (ar) مشتقات بيكوليناميد تعمل كمثبطات كيناز
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA33836B1 (ar) تركيبات صيدلانية تحتوي على ربطة استقبالات sigma
MA32232B1 (ar) مركبات ذات حلقية غير متجانسة جديدة واستخداماتها
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA32471B1 (ar) مركبات بورات استر و التراكيب الصيدلانية المحتوية على مركبات
MA33737B1 (ar) مشتقات الأنتراكينون واستخدامها
MA30394B1 (fr) Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p
MA33072B1 (ar) مركبات بيريدزينون
MA31710B1 (ar) (كاربوكسلالكيلين فينيل) فينلوكساميد، عمليات إنتاجه وإستعماله كدواء
MA38170A1 (fr) Nouveaux acides indanyloxydihydrobenzofuranylacétiques
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
MA31158B1 (ar) مركبات ثلاثية الحلقات واستخدامها كمعدلات لمستقبل جلايكورتيكود.
MA30262B1 (fr) Pesticides contenant une structure bis (amide) bicyclique.
MA30950B1 (fr) Nouveaux (aza) cyclohexanes carbonyles en tant que ligands du recepteur de dopamine d3.